most frequent causes of death in postmenopausal women in western countries.
1 For example, the figNot surprisingly, there is genuine concern ures for CVD applying to women largely reflect those amongst general practitioners and clinicians that for men, but women are on average 10 years older HRT use may result in an increased risk of venous than the corresponding male subject. In addition, thrombosis, stroke, myocardial infarction and the incidence of myocardial infarction in women hypertension. 12 lags behind that of men by almost 20 years. This draClinicians managing hypertensive menopausal matic difference is thought to largely reflect the loss women are often worried about prescribing HRT, of a hormonal protective factor in women against with the belief that HRT use may actually increase CVD, and replacement of oestrogens as hormone blood pressure (BP). 12 For example, there is little replacement therapy (HRT) was hypothesised to recdoubt that the use of high-dose oestrogen-containing tify this loss.
oral contraceptives in young women may be associaIndeed, many studies have suggested a significant ted with an increase in systolic and diastolic reduction in cardiovascular risk in postmenopausal BPs. 13,14 Such a situation results in 'supra-physiowomen taking oestrogen HRT.
2 On average, there is logical' state of oestrogen excess, which may have a a reduction in CVD by about 35%, with some evisignificant pressor effect on BP. By contrast, in normodence for benefits in stroke reduction from prospectensive post-menopausal women, the use of HRT does tive cohort data.
2-5 A policy statement by the Amernot appear to raise BP and may even lower it. [15] [16] [17] [18] [19] [20] ican College of Physicians has even suggested that This should not be surprising as HRT essentially HRT should be considered in 'all postmenopausal replaces oestrogen levels to the 'usual' physiological women' in view of its perceived benefits in CVD prelevels. However, a small number (Ͻ2%) of menovention. 6 A recent editorial in the American Journal pausal women taking oral natural oestrogens will of Cardiology states that HRT should even be condevelop a significant rise when starting therapy. 21 sidered as 'a first line agent for reducing LDL cholesThe concerns of clinicians about the effects of terol and raising HDL cholesterol' in menopausal HRT in hypertensive post-menopausal women are women, and recommended that 'every postmenoprobably justified as there have been few studies pausal woman with coronary artery disease' should addressing this issue in the literature. We previously be apprised of the benefits and risks of HRT.
7 Whilst estimated that to study the effects of HRT on BP in this optimism has been supported by many patho-100 symptomatic hypertensive post-menopausal physiological reasons and clinical data for the benewomen, it would be necessary to screen about 1000 fits of HRT in CVD prevention, 5,7 caution has also symptomatic post-menopausal women, and ultibeen expressed by the recent publication of studies mately even more post-menopausal women to find demonstrating an excess of deep venous thrombosis those that are actually symptomatic. 5 The ethics of (by two-to four-fold) in menopausal women taking such an exercise would also be detectable as HRT HRT [8] [9] [10] and an increasing awareness of the risk of would have to be withheld in 50% of them in any breast cancer, especially after 10 years' continuous large, prolonged placebo-controlled study. use (by 1.3-to 1.5-fold). There are also some doubts 23 where no change in mean BP over a median follow-up of 18 months, despite a rise in hypertensive menopausal women, BP should be measured initially and thereafter at least 6-monthly, mean weight. Nevertheless, we have noted a very small number of women in whom the BP did rise or if BP is labile or difficult to control, 3-monthly measurements should be made; and (4) if a hyperfollowing HRT use. 22 We extended our observations to a small group of women with uncontrolled hypertensive woman on HRT demonstrates a rise in BP, careful monitoring or observation and perhaps an tension, in whom HRT was prospectively discontinued, where no significant fall in mean BP was alteration or increase of their antihypertensive treatment should be given. Other factors, such as lipids noted, implying the lack of a significant pressor effect of HRT on BP. may speculate that continued deprivation of HRT There was also a trend towards a reduction in 
